![Kenneth Hillan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kenneth Hillan
Directeur/Membre du Conseil chez
SANGAMO THERAPEUTICS, INC.
Fortune : 5 378 $ au 30/06/2026
Profil
Kenneth J.
Hillan is currently an Independent Director at Sangamo Therapeutics, Inc. since 2020 and a Director at Zymeworks BC, Inc. since 2017.
Formerly, Dr. Hillan was CEO, Director & President-R&D Division at Achaogen, Inc. from 2017 to 2019; Independent Director at Relypsa, Inc. from 2015 to 2016; Independent Director at Zymeworks, Inc. from 2017 to 2024; SVP & Head-Roche Product Development, Asia Pacific at Genentech, Inc. from 2010 to 2011; Member of Roche Group from 1994 to 2011; Head-Therapeutics at 23andMe, Inc. from 2019 to 2021; and Chief Therapeutics Officer at Chrome Holding Co. from 2022 to 2023.
Dr. Hillan earned a doctorate from the University of Glasgow School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 12/06/2025 | 99 600 ( 0,02 % ) | 5 378 $ | 30/06/2026 |
Postes actifs de Kenneth Hillan
| Sociétés | Poste | Début |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 11/09/2020 |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Develops protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases | Directeur/Membre du Conseil | 03/02/2017 |
Anciens postes connus de Kenneth Hillan
| Sociétés | Poste | Fin |
|---|---|---|
| ZYMEWORKS INC. | Directeur/Membre du Conseil | 08/02/2024 |
| CHROME HOLDING CO. | Corporate Officer/Principal | 08/08/2023 |
23andMe, Inc.
 23andMe, Inc. Medical SpecialtiesHealth Technology Develops DNA analysis test kits | Corporate Officer/Principal | 01/06/2021 |
| ACHAOGEN | Directeur Général | 04/04/2019 |
| RELYPSA INC | Directeur/Membre du Conseil | 01/09/2016 |
Formation de Kenneth Hillan
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
85
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Sangamo Therapeutics, Inc.
 Sangamo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a genomic medicine company | Health Technology |
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Operates as a a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections | Health Technology |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Develops protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases | Health Technology |
Roche Group
 Roche Group Real Estate DevelopmentFinance Manages real estate properties | Finance |
23andMe, Inc.
23andMe, Inc. Medical SpecialtiesHealth Technology Develops DNA analysis test kits | Health Technology |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops non-absorbed polymeric drugs for applications in cardiovascular and renal diseases | Health Technology |
University of Glasgow School of Medicine
 University of Glasgow School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
23andMe Holding Co.
 23andMe Holding Co. BiotechnologyHealth Technology Operates as a genetic testing company | Health Technology |
Zymeworks, Inc.
 Zymeworks, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
